OncLive TV

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

Paolo A. Ascierto, MD, discusses findings from the SECOMBIT and DREAMseq trials and their implications for first-line treatment selection for patients with BRAF-mutant melanoma.

Caroline Robert, MD, PhD, discusses the role of adjuvant anti–PD-1 therapy in resected stage IIB/IIC melanoma based on findings from the KEYNOTE-716 and CheckMate 76K trials.

Charles B. Nguyen, MD, discusses the updated 2024 NCCN Guidelines and their effect on treatment decisions for non–clear cell RCC.

Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis assessing the prognostic value of HER2-low in early breast cancer management.

Mikkael A. Sekeres, MD, discusses the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes.

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of Dato-DXd for pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.